Wells Fargo’s Novavax NVAX Stock Holding History

Wells Fargo’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,267,100	Closed	-$7.98M	–	7295
2025 Q2	$7.98M	Hold	1,267,100	–	–	﹤0.01%	2104
2025 Q1	$8.12M	Buy	+1,267,100	New	+$10.5M	﹤0.01%	2022
2022 Q3	–	Sell	-10,000	Closed	-$514K	–	7144
2022 Q2	$514K	Buy	+10,000	New	+$518K	﹤0.01%	3728
2022 Q1	–	Sell	-1,800	Closed	-$258K	–	7583
2021 Q4	$258K	Buy	+1,800	New	+$309K	﹤0.01%	5121
2021 Q3	–	Sell	-14,300	Closed	-$3.04M	–	7341
2021 Q2	$3.04M	Buy	+14,300	New	+$2.62M	﹤0.01%	3321

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's NVAX Position: Q1 2026 in Review

Wells Fargo reduced its Novavax (NVAX) stake by 59% in Q1 2026, selling an estimated $894K and leaving 67,885 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #4103.

Wells Fargo first reported a position in NVAX in Q3 2013 and has held it in 50 quarters since. The position peaked at $63.7M in Q2 2015. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Wells Fargo held 67,885 shares of Novavax worth $553K as of Q1 2026.
Wells Fargo sold 98,664 Novavax shares in Q1 2026, an estimated $894K.
Novavax made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4103 holding.
Wells Fargo first reported a position in Novavax in Q3 2013 and has held it in 50 quarters since.
Wells Fargo's Novavax position peaked at $63.7M in Q2 2015.
257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.